The DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies
Open accessAbstract
The Janus kinase/signal transducer and activator of transcription (Jak/Stat) pathway was discovered 20 years ago as a mediator of cytokine signaling. Since this time, more than 2,500 articles have been published demonstrating the importance of this pathway in virtually all malignancies. Although there are dozens of cytokines and cytokine receptors, four Jaks, and seven Stats, it seems that interleukin-6–mediated activation of Stat3 is a principal pathway implicated in promoting tumorigenesis. This transcription factor regulates the expression of numerous critical mediators of tumor formation and metastatic progression. This review will examine the relative importance and function of this pathway in nonmalignant conditions as well as malignancies (including tumor intrinsic and extrinsic), the influence of other Stats, the development of inhibitors to this pathway, and the potential role of inhibitors in controlling or eradicating cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764 · cited 1×
“hepatocellular carcionoma, and pancreatic cancer).(57,116-121) Activation of Stat3 by VEGF, platelet-derived growth factor, IL-6, or IL-10 is responsible for various immunosuppressive activities, such as the blockade of dendritic-cell maturation and the release of IL-10, which inhibits T-cell and macrophage activation…”
BackgroundBowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743 · cited 1×
“In contrast to normal cells, in which Stat tyrosine phosphorylation occurs transiently, it has been determined that Stats 1, 3, and 5 are persistently tyrosine phosphorylated in most malignancies (particularly Stat3).(79-81) The mechanisms by which Stat3 is persistently or constitutively tyrosine phosphorylated in can…”
BackgroundMPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030270 · Cited by 1,449
Regulation of JAK–STAT signalling in the immune system
Shuai, K., & Liu, B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1226 · Cited by 1,372
JAK-STAT Signaling: From Interferons to Cytokines
Schindler, C., Levy, D. E., & Decker, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.r700016200 · Cited by 1,258
STAT3 Mutations in the Hyper-IgE Syndrome
Holland, S. M., DeLeo, F. R., Elloumi, H. Z., Hsu, A. P., Uzel, G., Brodsky, N., Freeman, A. F., Demidowich, A., Davis, J., Turner, M. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073687 · Cited by 1,221
Takeda, K., Clausen, B. E., Kaisho, T., Tsujimura, T., Terada, N., Förster, I., & Akira, S. (1999) · Immunity · doi:10.1016/s1074-7613(00)80005-9 · Cited by 1,220
NF-κB and STAT3 – key players in liver inflammation and cancer
He, G., & Karin, M. (2011) · Cell Research · doi:10.1038/cr.2010.183 · Cited by 1,197
Transcription factors as targets for cancer therapy
Darnell, J. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc906 · Cited by 1,194
Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome
Milner, J. D., Brenchley, J. M., Laurence, A., Freeman, A. F., Hill, B. J., Elias, K. M., Kanno, Y., Spalding, C., Elloumi, H. Z., Paulson, M. L., et al. (2008) · Nature · doi:10.1038/nature06764 · Cited by 1,157
Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome
Minegishi, Y., Saito, M., Tsuchiya, S., Tsuge, I., Takada, H., Hara, T., Kawamura, N., Ariga, T., Pasic, S., Stojkovic, O., et al. (2007) · Nature · doi:10.1038/nature06096 · Cited by 1,048
Th17 and regulatory T cells in mediating and restraining inflammation
Littman, D. R., & Rudensky, A. Y. (2010) · Cell · doi:10.1016/j.cell.2010.02.021 · Cited by 1,039
INTERLEUKIN-6: From Basic Science to Medicine—40 Years in Immunology
Kishimoto, T. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115806 · Cited by 1,024
Specific Inhibition of Stat3 Signal Transduction by PIAS3
Chung, C. D., Liao, J., Liu, B., Rao, X., Jay, P., Berta, P., & Shuai, K. (1997) · Science · doi:10.1126/science.278.5344.1803 · Cited by 980 · cited 1×
“tases, protein inhibitors of activated Stat, suppressor of cytokine signaling [SOCS] proteins).(23-31)”
BackgroundChaudhry, A., Samstein, R. M., Treuting, P., Liang, Y., Pils, M. C., Heinrich, J.-M., Jack, R. S., Wunderlich, F. T., Brüning, J. C., Müller, W., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.03.018 · Cited by 980
Bollrath, J., Phesse, T. J., von Burstin, V. A., Putoczki, T., Bennecke, M., Bateman, T., Nebelsiek, T., Lundgren-May, T., Canli, Ö., Schwitalla, S., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.002 · Cited by 946 · cited 2×
“While in EGFRvIII expressing GBMs Stat3 is required for tumorigenesis(182,183) There are conflicting data in murine APC models of intestinal cancer where one publication demonstrated that Stat3 was required for tumorigenesis while another suggested that Stat3 loss promoted tumor progression and invasion of intestinal…”
BackgroundEnhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931
The Myeloproliferative Disorders
Campbell, P. J., & Green, A. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmra063728 · Cited by 915
Marotta, L. L. C., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S. R., Bloushtain-Qimron, N., Kim, J. J., Choudhury, S. A., Maruyama, R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44745 · Cited by 911
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., et al. (1996) · Nature · doi:10.1038/379645a0 · Cited by 897
Serine phosphorylation of STATs
Decker, T., & Kovarik, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203481 · Cited by 887
Lesina, M., Kurkowski, M. U., Ludes, K., Rose-John, S., Treiber, M., Klöppel, G., Yoshimura, A., Reindl, W., Sipos, B., Akira, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.009 · Cited by 862
Murai, M., Turovskaya, O., Kim, G., Madan, R., Karp, C. L., Cheroutre, H., & Kronenberg, M. (2009) · Nature Immunology · doi:10.1038/ni.1791 · Cited by 850
Quintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood · doi:10.1182/blood-2009-04-214957 · Cited by 843 · cited 1×
“Preclinically, these inhibitors are extremely effective in abrogating disease in myeloproliferative models, which has led to their clinical testing.(91,146-148) The best studied is the Jak1/2 inhibitor INCB018424 (Incyte, Wilmington, DE), which is in phase III clinical trials and has shown significant clinical improve…”
BackgroundLiu, L., Okada, S., Kong, X.-F., Kreins, A. Y., Cypowyj, S., Abhyankar, A., Toubiana, J., Itan, Y., Audry, M., Nitschke, P., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110958 · Cited by 797
Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue
Yuan, Z.-L., Guan, Y.-J., Chatterjee, D., & Chin, Y. E. (2005) · Science · doi:10.1126/science.1105166 · Cited by 790
Sansone, P., Storci, G., Tavolari, S., Guarnieri, T., Giovannini, C., Taffurelli, M., Ceccarelli, C., Santini, D., Paterini, P., Marcu, K. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32533 · Cited by 779
Self-citationYoshikawa, H., Matsubara, K., Qian, G.-S., Jackson, P., Groopman, J. D., Manning, J. E., Harris, C. C., & Herman, J. G. (2001) · Nature Genetics · doi:10.1038/ng0501-29 · Cited by 722
Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation
Gough, D. J., Corlett, A., Schlessinger, K., Wegrzyn, J., Larner, A. C., & Levy, D. E. (2009) · Science · doi:10.1126/science.1171721 · Cited by 716
Alexander, W. S., & Hilton, D. J. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.091003.090312 · Cited by 701
Olkhanud, P. B., Damdinsuren, B., Bodogai, M., Gress, R. E., Sen, R., Wejksza, K., Malchinkhuu, E., Wersto, R. P., & Biragyn, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4316 · Cited by 684
Persistently Activated Stat3 Maintains Constitutive NF-κB Activity in Tumors
Lee, H., Herrmann, A., Deng, J.-H., Kujawski, M., Niu, G., Li, Z., Forman, S., Jove, R., Pardoll, D. M., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.015 · Cited by 683
Gao, S. P., Mark, K. G., Leslie, K., Pao, W., Motoi, N., Gerald, W. L., Travis, W. D., Bornmann, W., Veach, D., Clarkson, B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31871 · Cited by 666
Self-citationAggarwal, B. B., Kunnumakkara, A. B., Harikumar, K. B., Gupta, S. R., Tharakan, S. T., Koca, C., Dey, S., & Sung, B. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04911.x · Cited by 649
Interleukin 6: from bench to bedside
Nishimoto, N., & Kishimoto, T. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0338 · Cited by 642
Yang, J., Liao, X., Agarwal, M. K., Barnes, L., Auron, P. E., & Stark, G. R. (2007) · Genes & Development · doi:10.1101/gad.1553707 · Cited by 611
STAT proteins: From normal control of cellular events to tumorigenesis
Calò, V., Migliavacca, M., Bazan, V., Macaluso, M., Buscemi, M., Gebbia, N., & Russo, A. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10364 · Cited by 610
Huber, S., Gagliani, N., Esplugues, E., O'Connor, W., Huber, F. J., Chaudhry, A., Kamanaka, M., Kobayashi, Y., Booth, C. J., Rudensky, A. Y., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.01.020 · Cited by 583
Inflammation and Cancer: IL-6 and STAT3 Complete the Link
Bromberg, J., & Wang, T. C. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.009 · Cited by 542
Self-citationThe JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Hedvat, M., Huszar, D., Herrmann, A., Gozgit, J. M., Schroeder, A., Sheehy, A., Buettner, R., Proia, D., Kowolik, C. M., Xin, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.015 · Cited by 526
Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression
Fukuda, A., Wang, S. C., Morris, J. P., Folias, A. E., Liou, A., Kim, G. E., Akira, S., Boucher, K. M., Firpo, M. A., Mulvihill, S. J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.002 · Cited by 521
Induction of epithelial tubules by growth factor HGF depends on the STAT pathway
Boccaccio, C., Andò, M., Tamagnone, L., Bardelli, A., Michieli, P., Battistini, C., & Comoglio, P. M. (1998) · Nature · doi:10.1038/34657 · Cited by 519
Defective TNF-α-Induced Apoptosis in STAT1-Null Cells Due to Low Constitutive Levels of Caspases
Kumar, A., Commane, M., Flickinger, T. W., Horvath, C. M., & Stark, G. R. (1997) · Science · doi:10.1126/science.278.5343.1630 · Cited by 514
Identification of a Nuclear Stat1 Protein Tyrosine Phosphatase
ten Hoeve, J., de Jesus Ibarra-Sanchez, M., Fu, Y., Zhu, W., Tremblay, M., David, M., & Shuai, K. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.16.5662-5668.2002 · Cited by 507 · cited 1×
“tases, protein inhibitors of activated Stat, suppressor of cytokine signaling [SOCS] proteins).(23-31)”
BackgroundIlaria, R. L., & Van Etten, R. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31704 · Cited by 488
Carlesso, N., Frank, D. A., & Griffin, J. D. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.811 · Cited by 483
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours
Rebouissou, S., Amessou, M., Couchy, G., Poussin, K., Imbeaud, S., Pilati, C., Izard, T., Balabaud, C., Bioulac-Sage, P., & Zucman-Rossi, J. (2009) · Nature · doi:10.1038/nature07475 · Cited by 477 · cited 1×
“Somatic in-frame deletions in the gp130 receptor can lead to hyperactivation of the receptor and activation of Stat3 and the development of inflammatory hepatocellular adenomas in mice.(92) The receptor protein tyrosine phosphatase delta is frequently inactivated in glioblastoma (GBM) multiforme, head and neck, and lu…”
BackgroundRegulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment
Kortylewski, M., Xin, H., Kujawski, M., Lee, H., Liu, Y., Harris, T., Drake, C., Pardoll, D., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.018 · Cited by 474
The Yin and Yang of type I interferon activity in bacterial infection
Decker, T., Müller, M., & Stockinger, S. (2005) · Nature Reviews Immunology · doi:10.1038/nri1684 · Cited by 468
Regulation of gene-activation pathways by PIAS proteins in the immune system
Shuai, K., & Liu, B. (2005) · Nature Reviews Immunology · doi:10.1038/nri1667 · Cited by 447
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target
Chiarle, R., Simmons, W. J., Cai, H., Dhall, G., Zamo, A., Raz, R., Karras, J. G., Levy, D. E., & Inghirami, G. (2005) · Nature Medicine · doi:10.1038/nm1249 · Cited by 442
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Shuai, K., Halpern, J., ten Hoeve, J., Rao, X., & Sawyers, C. L. (1996) · PubMed · Cited by 434
Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis
Ancrile, B., Lim, K.-H., & Counter, C. M. (2007) · Genes & Development · doi:10.1101/gad.1549407 · Cited by 422
STAT3 Plays a Critical Role in KRAS -Induced Pancreatic Tumorigenesis
Corcoran, R. B., Contino, G., Deshpande, V., Tzatsos, A., Conrad, C., Benes, C. H., Levy, D. E., Settleman, J., Engelman, J. A., & Bardeesy, N. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0908 · Cited by 413 · cited 1×
“hepatocellular carcionoma, and pancreatic cancer).(57,116-121) Activation of Stat3 by VEGF, platelet-derived growth factor, IL-6, or IL-10 is responsible for various immunosuppressive activities, such as the blockade of dendritic-cell maturation and the release of IL-10, which inhibits T-cell and macrophage activation…”
BackgroundAvery, D. T., Deenick, E. K., Ma, C. S., Suryani, S., Simpson, N., Chew, G. Y., Chan, T. D., Palendira, U., Bustamante, J., Boisson-Dupuis, S., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091706 · Cited by 409
Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation
Yang, J., Chatterjee-Kishore, M., Staugaitis, S. M., Nguyen, H., Schlessinger, K., Levy, D. E., & Stark, G. R. (2005) · Cancer Research · doi:10.1158/0008-5472.939.65.3 · Cited by 405
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors
Lee, H., Deng, J., Kujawski, M., Yang, C., Liu, Y., Herrmann, A., Kortylewski, M., Horne, D., Somlo, G., Forman, S., et al. (2010) · Nature Medicine · doi:10.1038/nm.2250 · Cited by 395
Wernig, G., Kharas, M. G., Okabe, R., Moore, S. A., Leeman, D. S., Cullen, D. E., Gozo, M., McDowell, E. P., Levine, R. L., Doukas, J., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.02.009 · Cited by 390
Poschke, I., Mougiakakos, D., Hansson, J., Masucci, G. V., & Kiessling, R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3767 · Cited by 382
SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer
He, B., You, L., Uematsu, K., Zang, K., Xu, Z., Lee, A. Y., Costello, J. F., McCormick, F., & Jablons, D. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2232790100 · Cited by 380
Kortylewski, M., Swiderski, P., Herrmann, A., Wang, L., Kowolik, C., Kujawski, M., Lee, H., Scuto, A., Liu, Y., Yang, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1564 · Cited by 380
Interleukin-6 in bone metastasis and cancer progression
Ara, T., & DeClerck, Y. A. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.026 · Cited by 379
Autocrine IL-6 Signaling: A Key Event in Tumorigenesis?
Grivennikov, S., & Karin, M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2007.12.020 · Cited by 368
Chan, K. S., Sano, S., Kiguchi, K., Anders, J., Komazawa, N., Takeda, J., & DiGiovanni, J. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421032 · Cited by 356
Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth
Leong, P. L., Andrews, G. A., Johnson, D. E., Dyer, K. F., Xi, S., Mai, J. C., Robbins, P. D., Gadiparthi, S., Burke, N. A., Watkins, S. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0534764100 · Cited by 340
Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway
de la Iglesia, N., Konopka, G., Puram, S. V., Chan, J. A., Bachoo, R. M., You, M. J., Levy, D. E., DePinho, R. A., & Bonni, A. (2008) · Genes & Development · doi:10.1101/gad.1606508 · Cited by 336
Oh, S. T., Simonds, E. F., Jones, C., Hale, M. B., Goltsev, Y., Gibbs, K. D., Merker, J. D., Zehnder, J. L., Nolan, G. P., & Gotlib, J. (2010) · Blood · doi:10.1182/blood-2010-02-270108 · Cited by 330
Tartour, E., Pere, H., Maillere, B., Terme, M., Merillon, N., Taieb, J., Sandoval, F., Quintin-Colonna, F., Lacerda, K., Karadimou, A., et al. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9281-4 · Cited by 316
Jenkins, B. J., Grail, D., Nheu, T., Najdovska, M., Wang, B., Waring, P., Inglese, M., McLoughlin, R. M., Jones, S. A., Topley, N., et al. (2005) · Nature Medicine · doi:10.1038/nm1282 · Cited by 308
Protein tyrosine phosphatases in the JAK/STAT pathway
Xu, D. (2008) · Frontiers in Bioscience · doi:10.2741/3051 · Cited by 307
Th17 cells: a new fate for differentiating helper T cells
Chen, Z., & O’Shea, J. J. (2008) · Immunologic Research · doi:10.1007/s12026-007-8014-9 · Cited by 300
Veeriah, S., Brennan, C., Meng, S., Singh, B., Fagin, J. A., Solit, D. B., Paty, P. B., Rohle, D., Vivanco, I., Chmielecki, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900571106 · Cited by 299
Canonical and non-canonical JAK–STAT signaling
Li, W. X. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.08.008 · Cited by 290
Cooperative Epigenetic Modulation by Cancer Amplicon Genes
Rui, L., Emre, N. C. T., Kruhlak, M. J., Chung, H.-J., Steidl, C., Slack, G., Wright, G. W., Lenz, G., Ngo, V. N., Shaffer, A. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.013 · Cited by 283
Nelson, E. A., Walker, S. R., Weisberg, E., Bar-Natan, M., Barrett, R., Gashin, L. B., Terrell, S., Klitgaard, J. L., Santo, L., Addorio, M. R., et al. (2011) · Blood · doi:10.1182/blood-2009-11-255232 · Cited by 280
Levine, R. L., & Gilliland, D. G. (2008) · Blood · doi:10.1182/blood-2008-03-077966 · Cited by 279
Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin
Ng, D. C. H., Lin, B. H., Lim, C. P., Huang, G., Zhang, T., Poli, V., & Cao, X. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200503021 · Cited by 278
Liu, F., Zhao, X., Perna, F., Wang, L., Koppikar, P., Abdel-Wahab, O., Harr, M. W., Levine, R. L., Xu, H., Tefferi, A., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.020 · Cited by 273
(2003) · PubMed · Cited by 272
Zhang, Q., Wang, H. Y., Marzec, M., Raghunath, P. N., Nagasawa, T., & Wasik, M. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501959102 · Cited by 262
Redell, M. S., Ruiz, M. J., Alonzo, T. A., Gerbing, R. B., & Tweardy, D. J. (2011) · Blood · doi:10.1182/blood-2010-04-280123 · Cited by 257
Activated Signal Transducer and Activator of Transcription (STAT) 3
Silver, D. L., Naora, H., Liu, J., Cheng, W., & Montell, D. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3959 · Cited by 252
The Unholy Trinity: Inflammation, Cytokines, and STAT3 Shape The Cancer Microenvironment
Li, N., Grivennikov, S. I., & Karin, M. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.018 · Cited by 245
Diaz, N., Minton, S., Cox, C., Bowman, T., Gritsko, T., Garcia, R., Eweis, I., Wloch, M., Livingston, S., Seijo, E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1749 · Cited by 242
Ups and downs: The STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling
Regis, G., Pensa, S., Boselli, D., Novelli, F., & Poli, V. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.06.004 · Cited by 236
Berishaj, M., Gao, S. P., Ahmed, S., Leslie, K., Al-Ahmadie, H., Gerald, W. L., Bornmann, W., & Bromberg, J. F. (2007) · Breast Cancer Research · doi:10.1186/bcr1680 · Cited by 236
Self-citationSTAT3 controls myeloid progenitor growth during emergency granulopoiesis
Zhang, H., Nguyen-Jackson, H., Panopoulos, A. D., Li, H. S., Murray, P. J., & Watowich, S. S. (2010) · Blood · doi:10.1182/blood-2009-12-259630 · Cited by 232
Studebaker, A. W., Storci, G., Werbeck, J. L., Sansone, P., Sasser, A. K., Tavolari, S., Huang, T., Chan, M. W. Y., Marini, F. C., Rosol, T. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0400 · Cited by 229
Self-citationAcetylation of Stat1 modulates NF-κB activity
Krämer, O. H., Baus, D., Knauer, S. K., Stein, S., Jäger, E., Stauber, R. H., Grez, M., Pfitzner, E., & Heinzel, T. (2006) · Genes & Development · doi:10.1101/gad.364306 · Cited by 219
Signal Transducer and Activator of Transcription-5 Activation and Breast Cancer Prognosis
Nevalainen, M. T., Xie, J., Torhorst, J., Bubendorf, L., Haas, P., Kononen, J., Sauter, G., & Rui, H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.046 · Cited by 216
Clarke, J. L., Pao, W., Wu, N., Miller, V. A., & Lassman, A. B. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0128-6 · Cited by 214 · cited 1×
“Furthermore, with the development of small-molecule inhibitors of tyrosine kinases with relatively short half-lives, we may wish to consider developing and testing regimens using pulsatile high doses, which may result in more effective targeting, fewer adverse effects, and less acquired resistance.(184,185) Importantl…”
BackgroundDorff, T. B., Goldman, B., Pinski, J. K., Mack, P. C., Lara, P. N., Van Veldhuizen, P. J., Quinn, D. I., Vogelzang, N. J., Thompson, I. M., & Hussain, M. H. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3122 · Cited by 212
Morinobu, A., Gadina, M., Strober, W., Visconti, R., Fornace, A., Montagna, C., Feldman, G. M., Nishikomori, R., & O'Shea, J. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182618999 · Cited by 208
Angelis, P. M. D., Kravik, K., Tunheim, S. H., Haug, T., & Reichelt, W. H. (2004) · Molecular Cancer · doi:10.1186/1476-4598-3-11 · Cited by 206
Garnero, P., Thompson, E., Woodworth, T., & Smolen, J. S. (2010) · Arthritis & Rheumatism · doi:10.1002/art.25053 · Cited by 205
Ling, X., & Arlinghaus, R. B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2425 · Cited by 201
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3
Nelson, E. A., Walker, S. R., Kepich, A., Gashin, L. B., Hideshima, T., Ikeda, H., Chauhan, D., Anderson, K. C., & Frank, D. A. (2008) · Blood · doi:10.1182/blood-2007-12-129718 · Cited by 200
Hazan-Halevy, I., Harris, D., Liu, Z., Liu, J., Li, P., Chen, X., Shanker, S., Ferrajoli, A., Keating, M. J., & Estrov, Z. (2010) · Blood · doi:10.1182/blood-2009-10-230060 · Cited by 198
Dolled-Filhart, M. P., Camp, R. L., Kowalski, D. P., Smith, B. L., & Rimm, D. L. (2003) · PubMed · Cited by 196
STAT3 Ubiquitylation and Degradation by Mumps Virus Suppress Cytokine and Oncogene Signaling
Ulane, C. M., Rodriguez, J. J., Parisien, J.-P., & Horvath, C. M. (2003) · Journal of Virology · doi:10.1128/jvi.77.11.6385-6393.2003 · Cited by 193
Zhang, X., Yue, P., Fletcher, S., Zhao, W., Gunning, P. T., & Turkson, J. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.01.001 · Cited by 179
Autoregulation of the Stat3 Gene through Cooperation with a cAMP-responsive Element-binding Protein
Ichiba, M., Nakajima, K., Yamanaka, Y., Kiuchi, N., & Hirano, T. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.11.6132 · Cited by 175
Kermorgant, S., & Parker, P. J. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200806076 · Cited by 174
Xi, S., Gooding, W. E., & Grandis, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1208316 · Cited by 170
Lai, S. Y., Childs, E. E., Xi, S., Coppelli, F. M., Gooding, W. E., Wells, A., Ferris, R. L., & Grandis, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1208635 · Cited by 167
Stat3 Is a Negative Regulator of Intestinal Tumor Progression in ApcMin Mice
Musteanu, M., Blaas, L., Mair, M., Schlederer, M., Bilban, M., Tauber, S., Esterbauer, H., Mueller, M., Casanova, E., Kenner, L., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.049 · Cited by 166
The JAK2 exon 12 mutations: A comprehensive review
Scott, L. M. (2011) · American Journal of Hematology · doi:10.1002/ajh.22063 · Cited by 165
Acetylation and activation of STAT3 mediated by nuclear translocation of CD44
Lee, J.-L., Wang, M.-J., & Chen, J.-Y. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200812060 · Cited by 164
Zhang, M., Liu, Q., Mi, S., Liang, X., Zhang, Z., Su, X., Liu, J., Chen, Y., Wang, M., Zhang, Y., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002989 · Cited by 163
de la Iglesia, N., Konopka, G., Lim, K.-L., Nutt, C. L., Bromberg, J. F., Frank, D. A., Mischel, P. S., Louis, D. N., & Bonni, A. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.5385-07.2008 · Cited by 163
Self-citationMertens, C., & Darnell, J. E., Jr. (2007) · Cell · doi:10.1016/j.cell.2007.10.033 · Cited by 151
Wallner, L. P., Dai, J., Escara-Wilke, J. F., Zhang, J., Yao, Z., Lü, Y., Trikha, M., Nemeth, J. A., Zaki, M. H., & Keller, E. T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3447 · Cited by 148
Reciprocal Effects of STAT5 and STAT3 in Breast Cancer
Walker, S. R., Nelson, E. A., Zou, L., Chaudhury, M., Signoretti, S., Richardson, A. L., & Frank, D. A. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0238 · Cited by 146
Li, Y., Du, H., Qin, Y., Roberts, J., Cummings, O. W., & Yan, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0647 · Cited by 146
Zhang, Q., Wang, H. Y., Liu, X., & Wasik, M. A. (2007) · Nature Medicine · doi:10.1038/nm1659 · Cited by 141
Griffiths, D. S., Li, J., Dawson, M. A., Trotter, M. W. B., Cheng, Y., Smith, A. M., Mansfield, W. M., Liu, P., Kouzarides, T., Nichols, J., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2135 · Cited by 138
Herrmann, A., Kortylewski, M., Kujawski, M., Zhang, C., Reckamp, K. L., Armstrong, B., Wang, L. Q., Kowolik, C. M., Deng, J., Figlin, R. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0736 · Cited by 138
Xia, L., Wang, L., Chung, A. S., Ivanov, S., Ling, M. Y., Dragoi, A. M., Platt, A., Gilmer, T., Fu, X.-Y., & Chin, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202823200 · Cited by 137
Shao, H., Cheng, H. Y., Cook, R. G., & Tweardy, D. J. (2003) · PubMed · Cited by 136
Judd, L. M., Bredin, K., Kalantzis, A., Jenkins, B. J., Ernst, M., & Giraud, A. S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.07.018 · Cited by 134
Sun, Y., Chin, Y. E., Weisiger, E., Malter, C., Tawara, I., Toubai, T., Gatza, E., Mascagni, P., Dinarello, C. A., & Reddy, P. R. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804388 · Cited by 132
Minegishi, Y. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.07.013 · Cited by 131
Saitō, M., Nagasawa, M., Takada, H., Hara, T., Tsuchiya, S., Agematsu, K., Yamada, M., Kawamura, N., Ariga, T., Tsuge, I., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20100799 · Cited by 128
Kujawski, M., Zhang, C., Herrmann, A., Reckamp, K. L., Scuto, A., Jensen, M. C., Deng, J., Forman, S. J., Figlin, R. A., & Yu, H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1293 · Cited by 125
Kortylewski, M., Kujawski, M., Herrmann, A., Yang, C., Wang, L., Liu, Y., Salcedo, R., & Yu, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3031 · Cited by 122 · cited 1×
“5), underscoring its role in early development, whereas tissue-specific loss of Stat3 demonstrates its importance in regulating inflammation (Th17 cells, myeloid cells, Bregs, dendritic cells).(33,53-60)”
BackgroundTherapeutic potential of JAK2 inhibitors
Verstovšek, S. (2009) · Hematology · doi:10.1182/asheducation-2009.1.636 · Cited by 121
Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480
Xin, H., Herrmann, A., Reckamp, K. L., Zhang, W., Pal, S. K., Hedvat, M., Zhang, C., Liang, W. P., Scuto, A., Weng, S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1217 · Cited by 117
Cutting Edge: The Th1 Response Inhibits the Generation of Peripheral Regulatory T Cells
Caretto, D., Katzman, S. D., Villarino, A. V., Gallo, E., & Abbas, A. K. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0903412 · Cited by 115
Constitutive activation of Stat5b contributes to carcinogenesis in vivo.
Xi, S., Zhang, Q. H., Gooding, W. E., Smithgall, T. E., & Grandis, J. R. (2003) · PubMed · Cited by 114
Lnk constrains myeloproliferative diseases in mice
Bersenev, A., Wu, C., Balcerek, J., Jiang, J., Kundu, M., Blobel, G. A., Chikwava, K. R., & Tong, W. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42032 · Cited by 114
Phosphorylation–acetylation switch in the regulation of STAT1 signaling
Krämer, O. H., & Heinzel, T. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.10.007 · Cited by 112
Puchalski, T. A., Prabhakar, U., Jiao, Q., Berns, B., & Davis, H. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2581 · Cited by 112
STAT3: A multifaceted oncogene
Levy, D. E., & Inghirami, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604042103 · Cited by 107
Stat3 as a Potential Target for Cancer Immunotherapy
Kortylewski, M., & Yu, H. (2007) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211327.76266.65 · Cited by 98
Ray, S., Lee, C., Hou, T., Boldogh, I. R., & Brasier, A. R. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn419 · Cited by 98
Betts, B. C., Abdel-Wahab, O. I., Curran, S. A., Angelo, E. T. S., Koppikar, P., Heller, G., Levine, R. L., & Young, J. W. (2011) · Blood · doi:10.1182/blood-2011-06-363408 · Cited by 97
Hou, T., Ray, S., Lee, C., & Brasier, A. R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805941200 · Cited by 95
Yamashita, H., Nishio, M., Ando, Y., Zhang, Z., Hamaguchi, M., Mita, K., Kobayashi, S., Fujii, Y., & Iwase, H. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01095 · Cited by 94
Jenkins, B. J., Roberts, A. W., Greenhill, C., Najdovska, M., Lundgren–May, T., Robb, L. G., Grail, D., & Ernst, M. (2006) · Blood · doi:10.1182/blood-2006-08-040352 · Cited by 94
Ranger, J. J., Levy, D. E., Shahalizadeh, S., Hallett, M. T., & Muller, W. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1684 · Cited by 92
Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein
Fletcher, S., Drewry, J. A., Shahani, V. M., Page, B. D. G., & Gunning, P. T. (2009) · Biochemistry and Cell Biology · doi:10.1139/o09-044 · Cited by 90
Cytokine disbalance in common human cancers
Čulig, Z. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.12.010 · Cited by 90
Physiological significance of STAT proteins: investigations through gene disruption in vivo
Levy, D. E. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050395 · Cited by 87
Koppikar, P., Lui, V. W. Y., Man, D., Xi, S., Chai, R. L., Nelson, E. G., Tobey, A. B. J., & Grandis, J. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1328 · Cited by 86
Stat3 enhances transactivation of steroid hormone receptors
Miguel, F. D., Lee, S. O., Oñate, S. A., & Gao, A. C. (2003) · Nuclear Receptor · doi:10.1186/1478-1336-1-3 · Cited by 83
Ma, H., Lu, C., Ziegler, J., Liu, A., Sepulveda, A. R., Okada, H., Lentzsch, S., & Mapara, M. Y. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43706 · Cited by 80
Koppikar, P., Abdel-Wahab, O. I., Hedvat, C. V., Marubayashi, S., Patel, J. L., Goel, A. J., Kucine, N., Gardner, J. R., Combs, A. P., Vaddi, K., et al. (2010) · Blood · doi:10.1182/blood-2009-04-218842 · Cited by 79
Self-citationProlactin Inhibits BCL6 Expression in Breast Cancer through a Stat5a-Dependent Mechanism
Tran, T. H., Utama, F. E., Lin, J., Yang, N., Sjolund, A. B., Ryder, A., Johnson, K. J., Neilson, L. M., Liu, C., Brill, K. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2314 · Cited by 79
Smith, A. M., Qualls, J. E., O’Brien, K., Balouzian, L., Johnson, P. F., Schultz‐Cherry, S., Smale, S. T., & Murray, P. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.249235 · Cited by 78
Nelson, E. A., Sharma, S. V., Settleman, J. E., & Frank, D. A. (2011) · Oncotarget · doi:10.18632/oncotarget.296 · Cited by 76
Are STATS Arginine-methylated?
Komyod, W., Bauer, U., Heinrich, P. C., Haan, S., & Behrmann, I. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c400606200 · Cited by 75
Zhao, W. M., Jaganathan, S., & Turkson, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.154088 · Cited by 74
Boehm, A. L., Sen, M., Seethala, R. S., Gooding, W. E., Freilino, M. L., Wong, S. M. Y., Wang, S., Johnson, D. E., & Grandis, J. R. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.044636 · Cited by 74
Stat Acetylation--A Key Facet of Cytokine Signaling?
O’Shea, J. J., Kanno, Y., Chen, X., & Levy, D. E. (2005) · Science · doi:10.1126/science.1108164 · Cited by 70
Walker, S. R., Chaudhury, M., Nelson, E. A., & Frank, D. A. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.066316 · Cited by 68
Lui, V. W. Y., Boehm, A. L., Koppikar, P., Leeman‐Neill, R. J., Johnson, D. E., Ogagan, M. J., Childs, E. E., Freilino, M. L., & Grandis, J. R. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.032284 · Cited by 67
Horiguchi, N., Lafdil, F., Miller, A. M., Park, O., Wang, H., Rajesh, M., Mukhopadhyay, P., Fu, X. Y., Pacher, P., & Gao, B. (2010) · Hepatology · doi:10.1002/hep.23532 · Cited by 65
Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation
Friedbichler, K., Kerenyi, M. A., Kovačic, B., Li, G., Hoelbl‐Kovacic, A., Yahiaoui, S., Sexl, V., Müllner, E. W., Fajmann, S., Cerny‐Reiterer, S., et al. (2010) · Blood · doi:10.1182/blood-2009-12-258913 · Cited by 64
Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling
Zhang, T., Ma, J., & Cao, X. (2003) · Biochemical Journal · doi:10.1042/bj20030668 · Cited by 60
Reich, N. C. (2009) · Science Signaling · doi:10.1126/scisignal.290pe61 · Cited by 60
Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203549 · Cited by 59
Lack of toxicity of a STAT3 decoy oligonucleotide
Sen, M., Tosca, P. J., Zwayer, C., Ryan, M. J., Johnson, J. D., Knostman, K. A. B., Giclas, P. C., Peggins, J. O., Tomaszewski, J. E., McMurray, T. P., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0823-6 · Cited by 53
MAPK-induced Ser727 phosphorylation promotes SUMOylation of STAT1
Vanhatupa, S., Ungureanu, D., Paakkunainen, M., & Silvennoinen, O. (2007) · Biochemical Journal · doi:10.1042/bj20070620 · Cited by 52
Nakashima, Y., Kondo, M., Harada, H., Horiuchi, T., Ishinishi, T., Jôjima, H., Kuroda, K., Miyahara, H., Nagamine, R., Nakashima, H., et al. (2010) · Modern Rheumatology · doi:10.1007/s10165-010-0290-x · Cited by 50
Diffuse Large B Cell Lymphoma in Hyper-IgE Syndrome Due To STAT3 Mutation
Kumánovics, A., Perkins, S. L., Gilbert, H. M., Cessna, M. H., Augustine, N. H., & Hill, H. R. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9452-z · Cited by 50
An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells.
Aaronson, D. S., Muller, M., Neves, S. R., Chung, W.-C., Jayaram, G., Iyengar, R., & Ram, P. T. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.02.006 · Cited by 47
Betts, B., Angelo, E. S. S., Kennedy, M. G., & Young, J. W. (2011) · Blood · doi:10.1182/blood-2011-06-363390 · Cited by 38
Reindl, W., Weiß, S., Lehr, H., & Förster, I. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02473.x · Cited by 31
Serine Phosphorylation of Stat6 Negatively Controls Its DNA-Binding Function
Maiti, N. R., Sharma, P., Harbor, P. C., & Haque, S. J. (2005) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2005.25.553 · Cited by 27
Regulation of Stat3 transcriptional activity by the conserved LPMSP motif for OSM and IL‐6 signaling
Sun, W. Y., Snyder, M., Levy, D. E., & Zhang, J. J. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.09.054 · Cited by 25
Stewart, C. A., & Trinchieri, G. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.008 · Cited by 24
Serine phosphorylation of Stat5 proteins in lymphocytes stimulated with IL-2
Xue, H. (2002) · International Immunology · doi:10.1093/intimm/dxf101 · Cited by 24
Stat3-Driven Cancer-Related Inflammation as a Key Therapeutic Target for Cancer Immunotherapy
Kato, T. (2011) · Immunotherapy · doi:10.2217/imt.11.26 · Cited by 8
Dose-Dense Chemotherapy for Breast Cancer: What Does the Future Hold?
Morris, P. G., McArthur, H. L., Hudis, C. A., & Norton, L. (2010) · Future Oncology · doi:10.2217/fon.10.59 · Cited by 8
At 17, In-10's Passion Need Not Inflame
Stewart, C. A., & Trinchieri, G. (2011) · Immunity · doi:10.1016/j.immuni.2011.04.004 · Cited by 5
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Obesity and inflammation: the linking mechanism and the complications
Ellulu, M. S., Patimah, I., Khaza’ai, H., Rahmat, A., & Abed, Y. (2017) · Archives of Medical Science · doi:10.5114/aoms.2016.58928 · Cited by 1,982
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Razumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,729
Kambe, T., Tsuji, T., Hashimoto, A., & Itsumura, N. (2015) · Physiological Reviews · doi:10.1152/physrev.00035.2014 · Cited by 1,158
Metadata
- Authors
- Sansone, P., & Bromberg, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-03-20
- Volume
- 30
- Issue
- 9
- Pages
- 1005-1014
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2007501395
- Cited by
- 515
- References
- 184
- FWCI
- 24.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.